Sarcoidosis appears to follow two main trajectories, and clinical and treatment features at diagnosis may help predict whether the disease will resolve within the first few years or persist, according to a large study in Sweden involving more than 9,000 adult patients. About seven in 10 patients had few…
News
The first participants have been enrolled in a global clinical trial that will test Priovant Therapeutics’ oral therapy candidate brepocitinib against a placebo in people with cutaneous sarcoidosis (CS) — a type of the autoimmune disease, with no approved treatments, in which clumps of immune cells form in…
Manual workers are overrepresented among people with sarcoidosis, a study in France showed. The trend is more pronounced when the disease involves the lungs (pulmonary sarcoidosis). This supports the hypothesis that occupational exposure to environmental toxins such as dust and chemicals increases the risk of sarcoidosis. It also…
Ear, nose, and throat (ENT) conditions may be underdiagnosed among adults with sarcoidosis, a large U.S. database study suggests. Research showed that sarcoidosis patients had more than 45% higher odds of having recorded diagnoses of sinus, swallowing, voice, and cranial nerve-related conditions than their matched peers without sarcoidosis. The…
The Foundation for Sarcoidosis Research (FSR) has selected more than a dozen clinical centers to serve as inaugural sites for its newly launched U.S.-based registry that aims to enroll at least 2,000 people with sarcoidosis. The FSR Clinical Data Registry will help support high-quality, standardized clinical data…
The Foundation for Sarcoidosis Research (FSR) is teaming up with the Patient Advocate Foundation to offer a new support program for people with sarcoidosis who need help navigating insurance, disability benefits, and other financial challenges. “For far too long, patients living with sarcoidosis have had to navigate…
People with pulmonary sarcoidosis who undergo a lung transplant face greater short-term risks after surgery but have better long-term survival compared with individuals undergoing the procedure due to other lung conditions. Those are the key findings of a large U.S. study that investigated outcomes among people for whom the…
Nearly 4 in 10 people with pulmonary sarcoidosis had a relapse after reducing or stopping treatment, according to a review of more than 50 published studies. Most studies with timing data reported relapses occurring within 1.5 years of reducing or discontinuing treatment. Black patients and those with more advanced…
The Ann Theodore Foundation (ATF) and the Milken Institute have awarded $600,000 to three early-career researchers studying sarcoidosis in the U.S., with the goal of improving understanding of the disease, as well as its treatment and care. The new grant program, called Ann Theodore Foundation Learning Opportunities…
The antimalarial medication hydroxychloroquine may help treat uveitis, a type of eye inflammation, in some people with ocular sarcoidosis, a study reports. Specifically, over half of the 42 people with sarcoidosis-related uveitis (SAU) responded to hydroxychloroquine, sold under the brand names Plaquenil and Sovuna, with generics available. This allowed…
Recent Posts
- Study finds sarcoidosis may follow 2 distinct paths after diagnosis
- Global trial now underway to test oral therapy for sarcoidosis in the skin
- As I decipher ongoing liver issues, at least my treasured coffee is good for me
- Study links manual work to higher risk of sarcoidosis
- Study points to overlooked ENT problems in adults with sarcoidosis
- Foundation launches sarcoidosis research registry across 13 US sites
- Sharing the painful truth can comfort chronic illness patients
- New partnership expands insurance support for people with sarcoidosis
- A sarcoidosis lung transplant brings high hopes for long-term health
- When living with sarcoidosis, it helps to be ‘Simply More’